INVEST-REGISTRY: Minimally Invasive Endoscopic Surgical Treatment With Apollo/Artemis in Patients With Brain Hemorrhage

Inclusion Criteria: * Patient age 022 years or older * Supratentorial brain hemorrhage, which may be: 1. Intracerebral (ICH) 2. Primarily Intracerebral (ICH) with a component of intraventricular hemorrhage (IVH) 3. Primarily intraventricular hemorrhage (IVH) with a component of ICH 4. Intraventricular hemorrhage (IVH) * Patient does not qualify for the concurrent INVEST Feasibility study Exclusion Criteria: * Imaging * Expanding hemorrhage on stability CT/MR scan * "Spot sign" identified on CTA (May perform a second CTA at 12 hours to demonstrate resolution) * Hemorrhagic lesion such as a vascular malformation (cavernous malformation, AVM etc), aneurysm, neoplasm * Hemorrhagic conversion of an underlying ischemic stroke * Infratentorial hemorrhage * Midbrain extension/involvement * Coagulation Issues * Absolute and imminent (within 7 days of treatment) requirement for long-term, full-dose, anti-coagulation (e.g., Mechanical valve replacement (bio-prostatic valve is permitted), high risk atrial fibrillation) * Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency * Uncorrected platelet count \< 100 x 103 cells/mm3 or known platelet dysfunction * INR \> 1.45, elevated prothrombin time or activated partial thromboplastin time (aPTT), which cannot be corrected or otherwise accounted for (i.e., lupus anti-coagulant) * Patient Factors * High risk condition for ischemic stroke (high risk Afib (e.g., mitral stenosis with Afib), symptomatic carotid stenosis) * Requirement for emergent surgical decompression or uncontrolled ICP after EVD * Unable to obtain consent from patient or appropriate surrogate (for patients without competence) * Pregnancy, breast-feeding, or positive pregnancy test \[either serum or urine\] (Woman of child-bearing potential must have a negative pregnancy test prior to the study procedure.) * Evidence of active infection \[indicated by fever (at or over 100.7 °F) and/or open draining wound\] at the time of randomization * Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 180 days. * Based on investigator's judgment, patient does not have the necessary mental capacity to participate or is unwilling or unable to comply with protocol follow up appointment schedule. * Active drug or alcohol use or dependence that, in the opinion of the site investigator would interfere with adherence to study requirements. * Currently participating in another interventional (drug, device, etc) research project.